BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 30922146)

  • 1. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
    Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
    J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
    Cicero AFG; Fogacci F; Cincione I
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1031-1038. PubMed ID: 34197267
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
    N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
    Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
    J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Bempedoic Acid in Clinical Practice.
    Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.
    Zhao X; Ma X; Luo X; Shi Z; Deng Z; Jin Y; Xiao Z; Tan L; Liu P; Jiang S; Shu Y; Tang B; Qiu C
    BMC Pharmacol Toxicol; 2020 Dec; 21(1):86. PubMed ID: 33276805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
    J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.
    Lalwani ND; Hanselman JC; MacDougall DE; Sterling LR; Cramer CT
    J Clin Lipidol; 2019; 13(4):568-579. PubMed ID: 31202641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
    Bays HE; Bloedon LT; Lin G; Powell HA; Louie MJ; Nicholls SJ; Lincoff AM; Nissen SE
    J Clin Lipidol; 2024; 18(1):e59-e69. PubMed ID: 37951797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
    Nissen SE; Lincoff AM; Brennan D; Ray KK; Mason D; Kastelein JJP; Thompson PD; Libby P; Cho L; Plutzky J; Bays HE; Moriarty PM; Menon V; Grobbee DE; Louie MJ; Chen CF; Li N; Bloedon L; Robinson P; Horner M; Sasiela WJ; McCluskey J; Davey D; Fajardo-Campos P; Petrovic P; Fedacko J; Zmuda W; Lukyanov Y; Nicholls SJ;
    N Engl J Med; 2023 Apr; 388(15):1353-1364. PubMed ID: 36876740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials.
    Lekuona I; Pintó X
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():58-64. PubMed ID: 33966815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
    Laufs U; Ballantyne CM; Banach M; Bays H; Catapano AL; Duell PB; Goldberg AC; Gotto AM; Leiter LA; Ray KK; Bloedon LT; MacDougall D; Zhang Y; Mancini GBJ
    J Clin Lipidol; 2022; 16(3):286-297. PubMed ID: 35346603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties.
    Masana Marín L; Plana Gil N
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():53-57. PubMed ID: 33966814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
    Brandts J; Ray KK
    Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bempedoic Acid: A New Drug for an Old Problem.
    Nguyen D; Du N; Sulaica EM; Wanat MA
    Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.